Infections caused by Stenotrophomonas maltophilia in recipients of hematopoietic stem cell transplantation

Frontiers in Oncology

Volumn 4 AUG, Issue , 2014, Pages

  Al Anazi, K A ^a   Al Jasser, A M ^b  

^a KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^b MINISTRY OF HEALTH   (Saudi Arabia)

Author keywords

Bacteremia; Drug resistance; Hematopoietic stem cell transplantation; Neutropenia; Stenotrophomonas maltophilia

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; BETA LACTAM; CARBAPENEM; CEFOPERAZONE PLUS SULBACTAM; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; DOXYCYCLINE; GATIFLOXACIN; IMIPENEM; LATAMOXEF; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; SULFADIAZINE SILVER; TIGECYCLINE; TIMENTIN; TROVAFLOXACIN; UNINDEXED DRUG;

ARTICLE; BACTEREMIA; BACTERIAL INFECTION; CATHETER INFECTION; COMPUTER ASSISTED TOMOGRAPHY; FLOW CYTOMETRY; FLUORESCENCE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MORBIDITY; MORTALITY; PERITONITIS; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; SEPTIC SHOCK; STENOTROPHOMONAS MALTOPHILIA; SURGICAL INFECTION; URINARY TRACT INFECTION;

EID: 84906261103     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00232     Document Type: Article

References (126)

1. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev (1998) 11(1): 57-80.
2. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev (2012) 25 (1): 2-41.
3. Lewis SS, Zaas A. Stenotrophomonas maltophilia. UpToDate (2013). Topic 13961, version 7.0: pages: 1-7.
4. Falagas ME, valkimadi P-E, Huang Y-T, Matthaiou DK, Hsueh P-R. Therapeutic options for Stenotrophomonas infections beyond cotrimoxazole: a systematic review. J Antimicrob Chemother (2008) 62: 889-894.
5. Al-Anazi KA, Al-Jasser AM. Bacteremia due to Stenotrophomonas maltophilia in patients with hematological malignancies. Kuwait Med J (2006) 38 (3): 214-219.
6. Micozzi Al, Venditti M, Monaco M, Friedrich A, Taglietti F, Santilli S, Martino P. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis (2000) 31: 705-711.
7. Tada K, Kurosawa S, Hiramoto N, Okinaka K, Ueno N, Asakura Y et al. Stenotrophomonas maltophilia infection in hemotopoietic SCT recipients: high mortality due to pulmonary hemorrhage. Bone Marrow Transplant (2013) 48: 74-79.
8. Araoka H, Fujii T, Izutsu K, Kimura M, Nishida A, Ishiwata K et al. Rapidly progressive pulmonary hemorrahage caused by Stenotrophomonas maltophilia in hematologic malignancy. Transplant Infect Dis (2012) 14 (4): 355-363.
9. Labarca JA, Leber AL, Kern VL, Territo MC, Brankovic LE, Bruckner DA et al. Outbreak of Stenotrophomonas maltophilia bacteremia in allogeneic bone marrow transplant patients. Role of severe neutropenia and mucositis. Clin Infect Dis (2000) 30: 195-197.
10. Klausner JD, Zukerman C, Limaye AP, Corey L. Outbreak of Stenotrophomonas maltophilia bacteremia among patients undergoing bone marrow transplantation: association with faulty replacement of hand washing soap. Infect Control Hosp Epidemiol (1999) 20 (11): 756-758.
11. Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis (2007) 45: 1602-1609.
12. Apisarnthanarak A, Mayfield JL, Garison T, McLendon PM, DiPerso JF, Fraser VJ, Polish LB. Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study. Infect Control Hosp Epidemiol (2003) 24 (4): 269-274.
13. Yeshurun M, Grafter-Gvili A, Thaler M, Keller N, Nagler A, Shimoni A. Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience. Infection (2010) 38 (3): 211-215.
14. Chaplow R, Palmer B, Heyderman R, Moppett J, Marks DI. Stenotrophomonas maltophilia bacteremia in 40 hematology patients: risk factors, therapy and outcome. Bone marrow Transplant (2010) 45: 1109-1110.
15. Caylan R, Yilmaz G, Sucu N, Bayraktar O, Aydin K, Kaklikkaya N, Aydin F, Köksal I. Nosocomial Stenotrophomonas maltophilia infections in a university hospital. Mikrobiyol Bul (2005) 39 (1): 25-33.
16. Muder RR. Optimizing therapy for Stenotrophomonas maltophilia. Semin Respir Crit Care Med (2007) 28 (6): 672-677.
17. Looney WJ, Narita M, Mühleman K. Stenotrophomonas multophilia: an emerging opportunist human pathogen. Lancet Infect Dis (2009) 9: 213-223.
18. Lai CH, Chi CY, Chen HP, Chen TL, Lai CJ, Fung CP et al. Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia bacteremia. J Microbiol Immunol Infection (2004) 37 (6): 350-358.
19. Boktour M, Hanna H, Ansari S, Bahna B, Hachem R, Tarrand J, et al. Central venous catheter and Stenotrophomonas maltiphilia bacteremia in cancer patients. Cancer (2006), 106: 1967-1973.
20. Fletcher S. Catheter-related bloodstream infection. Contin Edu Anaesth Crit Care Pain (2005) 5 (2): 49-51.
21. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P. O'Grady NP. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infections: 2009 update by the Infections Disease Society of America. Clin Infect Dis 2009: 49: 1-45.
22. Hanna H, Afif C, Alakech B, Boktour M, Tarrand J, Hachem R, et al. Central venous catheter-related bacteremia due to Gramnegative bacilli: significance of catheter removal in preventing disease. Infect Control Hosp Epidemiol (2004), 25 (8): 646-649.
23. Dias MBS, Habert AB, Burrasca V, Stempliuk V, Ciolli A, Araujo RE, et al. Salvage of long-term central venous catheters during an outbreak of Pseudomonas putida and Stenotrophomonas maltophilia infections associated with contaminated heparin catheter-lock solution. Infect Control Hosp Epidemiol (2008), 29 (2): 125-130.
24. Crnich CJ, Maki DG. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. II. Long-term devices. Clin Infect Dis (2002), 34: 1362-1368.
25. Shiratori S, Wakasa K, Okada K, Sugita J, Akizawa K, Shigematsu A, et al. Stenotrophomonas maltophilia infection during allogeneic hematopoietic stem cell transplantation: a single-center experience. Clin Transplant (2014), March 13. doi: 10.1111/ctr. 12356.
26. Nseir S, Di Pompeo C, Brisson H, Dewavrin F, Tissier S, Diarra M, et al. Intensive care unit-acquired Stenotrophomonas maltophilia: incidence, risk factors and outcome. Crit Care (2006), 10: R143, doi: 10.1186/cc 5063.
27. Wood GC. Treatment of recurrent Stenotrophomonas ventilatorassociated pneumonia with doxycycline and aerosolized colistin. Ann pharmacother (2010), 44 (10): 1665-1668.
28. Mendoza DL, Darin M, Waterer GW, Wunderink RG. Update on Stenotrophomonas maltophilia infection in the ICU. Clin Pulm Med (2007), 14 (1): 17-22.
29. Mayer SA, Pastores S, Adamu M, Halpern NA, Young JW, Jakubowski A. Outcomes of adult allogeneic hematopoietic stem cell transplant patients admitted to the intensive care unit in the peri-transplant period. Chest (2008), 143 (4Meeting Abstracts): p 60003.doi:10.1378/chest.134.4_MeetingAbstracts. p60003.
30. Mori M, Kitagawa T, Sasaki Y, Yamamoto K, Onaka T, Yonezawa A, et al. Lethal pulmonary hemorrhage caused by Stenotrophomonas maltophilia pneumonia in a patient with acute myeloid leukemia. Kansenshogaku Zasshi (2012) 86 (3): 300-305.
31. Gupta S, Jain A, Werneke CL, Gupta A, Shannon VR, Morice RC, et al. Outcome of alveolar hemorrhage in hematopoietic stem cell transplant recipients. Bone Marrow Transplant (2007) 40: 71-78.
32. Mori M, Tsunemine H, Imada K, Ito K, Kodaka T, Takahashi T. Life-threatening hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in the treatment of hematologic diseases. Ann Hematol (2014) 93 (6): 901-911.
33. Wang W-S, Liu C-P, Lee C-M, Huang F-Y. Stenotrophomonas maltophilia bacteremia in adults: four years' experience in a medical center in northern Taiwan. J Microbiol Immunol Infect (2004), 37: 359-365.
34. Naidu P, Smith S. A review of 11 years of Stenotrophomonas maltophilia blood isolates at a tertiary care institute in Canada. Can J Infect Dis Med Microbiol (2012), 23 (4): 165-169.
35. Senol E, Des Jardin J, Stark PC, Barefoot L, Syndman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis (2002), 34: 1653-1656.
36. Wu P-S, Lu C-Y, Chang L-Y, Hsueh P-R, Lee P-S, Chen J-M, et al. Stenotrophomonas maltophilia bacteremia in pediatric patients-a 10-year analysis. J Microbiol Immunol Infect (2006), 39: 144-149.
37. Hotta G, Matsumura Y, Kato K, Nakano S, YunoKi T, Yamamoto M et al. Risk factors and clinical characteristics of Stenotrophomonas maltophilia bacteremia: a comparison with bacteremia due to other glucose-non fermenters. Kansenshogaku Zasshi (2013) 87 (5): 596-602.
38. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis (2001) 32 (Suppl 2): 104-113.
39. Memish ZA, Shibl AF, Kambal AM, Ohaly YA, Ishaq A, Livermore DM. Antimicrobial resistance among non-fermentating Gramnegative bacteria in Saudi Arabia. J Antimicorb Chemother (2012) 67: 1701-1705.
40. Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect Dis (2007) 26 (4): 229-237.
41. Averbuch D, Cordonnier C, Livermore DM, Mikulska M, Orasch C, Viscoli C et al on behalf of ECIL 4, a joint venture of EBMT, EORTC, ICHS, ESGICH/ESCMID and ELN. Targeted therapy against multi-resistant bacteria in leukemia and hematopoietic stem cell transplant recipients: guidelines of the 4th Europian Conference on Infections in Leukemia (ECIL-4, 2011). Haematologica (2013) 98 (12): 1836-1847.
42. Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, et al. Antimicrobial susceptibility of 22,746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 Study. J Antimicrob Chemother (2013), 68 (Supp l): i7-i22.
43. Brooke SJ. New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen. Expert Rev Anti Infect Ther (2014), 12 (1): 1-4.
44. Gulmez D, Cakar A, Sener B, Karakaya J, Hascelik G. Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J Infect Chemother (2010), 16 (5): 322-328.
45. Liaw S-J, Teng L-J, Hsueh P-R, Ho S-W, Luh T-T. In vitro activiteis of antimicrobial combinations against clinical isolates of Stenotrophomonas maltophilia. J Formos Med Assoc (2002), 101(7): 495-501.
46. Abbott IJ, Slavin MA, Turnidge JD, Thursky KA, Worth LJ. Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment. Expert Rev Anti Infect Ther (2011), 9 (4): 471-488.
47. Samonis G, Karageogopoulos DE, Maraki S, Levis P, Dimopoulou D, Spernovasillis NA, et al. Stenotrophomonas maltophilia infections in a general hospital: patient characteristics, antimicrobial susceptibility and treatment outcome. PLoS ONE (2012), 7 (5): é 37375. doi:10.1371/journal. pone.0037375.
48. Betriu C, Sänchez A, Palau ML, Gomez M, Picazo JJ. Antibiotic resistance surveillance of Stenotrophomonas maltophilia, 1993-1999. J Antimicrob Chemother 2001, 48: 152-154.
49. Alonso A, Martinez JL. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother (1997) 41(5): 1140-1142.
50. Li X-Z, Zhang L, Poole K. SmeC, an outer membrane multidrug efflux protein of Stenotrophomonas maltophilia. Antimicrob Agents Chemother (2002) 46 (2): 333-343.
51. Li X-Z, Zhang L, Mckay GA, Poole K. Role of the acetyltransferase AAC(6')-Iz modifying enzyme in aminoglycoside resistance in Stenotrophomonas maltophilia. J Antimicrob Chemother (2003) 51: 803-811.
52. Fihman V, Le Monnier A, Corvec S, Jaureguy F, Tankovic J, Jacquir H, et al. Stenotrophomonas maltophilia--the most worrisome threat among unusual non-fermentative Gramnegative bacilli from hospitalized patients: a prospective multicenter study. J Infect (2012), 64 (4): 391-398.
53. Wang YL, Scipione MR, Dubrovskaya Y, Papadopoulos J. Monotherapy with fluoroquinolones or trimethoprimsulfamethoxazole for treatment of Stenotrophomonas maltophilia infections. Antimicrob Agents Chemother (2014), 58 (1): 176-182.
54. Chung H-S, Hong SG, Kim YR, Shin KS, Whang DH, Ahn JY, et al. Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates. J Korean Med Sci (2013), 28: 62-66.
55. Rhee J-Y, Choi JY, Choi M-J, Song J-H, Peck KR, Ko KS. Distinct groups and antimicrobial resistance of clinical Stenotrophomonas complex isolates from Korea. J Med Microbiol (2013), 62: 748-753.
56. Naeem T, Absar M, Somily AM. Antibiotic resistance among clinical isolates of Stenotrophomonas maltophilia at a teaching hospital in Riyadh, Saudi Arabia. J Ayub Med Coll Abbottabad (2012), 24 (2): 30-33.
57. Toleman MA, Bennett PM, Bennett DMC, Jones RN, Walsh TR. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis (2007) 13 (4): 559-565.
58. Song JH, Sung JY, Kwon KC, Park JW, Cho HH, Shin SY et al. Analysis of acquired resistance genes in Stenotrophomonas maltophilia. Korean J Lab Med (2010) 30 (3): 295-300.
59. Alonso A, Sanchez P, Martinez JL. Stenotrophomonas maltophilia D457R contains a cluster of genes from Gram-positive bacteria involved in antibiotic and heavy metal resistance. Antimicrob Agents Chemother (2000) 44 (7): 1778-1782.
60. Tan CK, Liaw SJ, Yu CJ, Teng LJ, Hsueh PR. Extensively drugresistant Stenotrophomonas maltophilia in a tertiary care hospital in Taiwan: microbiologic characteristics, clinical features and outcome. Diagn Microbiol Infect Dis (2008) 60 (2): 205-210.
61. McKay GA, Woods DE, MacDonald KL, Poole K. Role of phosphoglucomutase of Stenotrophomonas maltophilia in lipopolysaccharide biosynthesis, virulence and antibiotic resistance. Infect Immunol (2003) 71 (6): 3068-3075.
62. Zhang L, Li X-Z, Poole K. SmeDEF multidrug efflux pump contributes to intrinsic multidrug resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother (2001) 45 (12): 3497-3503.
63. Metan G, Uzun O. Impact of initial antimicrobial therapy in patients with bloodstream infections caused by Stenotrophomonas maltophilia. Antimicrob Agents Chemother (2005) 49 (9): 3980-3981.
64. Gordon NC, Wareham DW. Novel variants of the Smqnr family of quinolone resistance genes in clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother (2010), 65: 483-489.
65. Karunanidhi A, Thomas R, van Belkum A, Neela V. In vitro antimicrobial and anitibiofilm activities of chlorogenic acid against clinical isolates of Stenotrophomonas maltophilia including the trimethoprim/sulfamethoxazole resistant strain. BioMed Res Int (2013) Article ID 392058, pages: 1-7. http://dx.doi.org/10.1155/2012/392058.
66. Di Bonaventura G, Spedicato I, D'Antoniop, Robuffo I, Piccolomini R. Biofilm formation by Stenotrophomonas maltophilia: modulation by quinolones, trimethoprim-sulfamethoxizole and ceftazidime. Antimicrob Agents Chemother (2004) 48 (1): 151-160.
67. Crossman LC, Gould VC, Dow JM, Vernikos GS, Okazaki A, Sebaihia M et al. The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants. Genome Biol (2008) 9 (4): R74, pages: 1-13.
68. Zhang L, Morrison M, Cuiv PO, Evans P, Rickard CM. Genome sequence of Stenotrophomonas maltophilia strain AU 12-09 isolated from an intravascular catheter. Genome Announc (2013) 1 (3): e 00195-13. doi: 10.1128/genomeA. 00195-13.70.
69. Chen C-H, Huang C-C, Chung T-C, Hu R-M, Huang Y-W, Yang T-C. Contribution of resistance-nodulation-division efflux pump operon Sme U1-V-W-U2-X to multidrug resistance of Stenotrophomonas maltophilia. Antimicrob Agents Chemother (2011) 55 (2): 5826-5833.
70. Chang Y-C, Tsai M-J, Huang Y-W, Chung T-C, Yang T-C. SmQnrR, a DeoR-type transcriptional regulator, negatively regulates the expression of Smqnr and SmtcrA in Stenotrophomonas maltophilia. J Antimicrob Chemother (2011), 66: 1024-1028.
71. Lin C-W, Huang Y-W, Hu R-M, Yang T-C. Sme OP-tolCsm efflux pump contributes to the multidrug resistance of Stenotrophomonas maltophilia. Antimicrob Agents Chemother (2014), 58 (4): 2405-2408.
72. Huang Y-W, Hu M-R, Yang T-C. Role of the pcm-tolCsm operon in the multidrug resistance of Stenotrophomonas maltophilia. J Antimicrob Chemother (2013), 68 (9): 1987-1993.
73. Hu LF, Chang X, Ye Y, Wang ZX, Shao YB, Shi W, et al. Stenotrophomonas maltophilia resistance to trimethoprim/sulfamethoxazole mediated by acquisition of sul and dfrA genes in a plasmid-mediated class/integron. Int J Antimicrob Agents (2011), 37 (3): 230-234.
74. Toleman MA, Bennett PM, Walsh TR. ISCR elements: novel gene-capturing systems of the 21st century? Microbiol Mol Biol Rev (2006), 70 (3): 296-316.
75. Neela V, Rankouhi SZ, van Belkum A, Goering RV, Awang R. Stenotrophomonas maltophilia in Malaysia: molecular epidemiology and trimethoprim-sulfamethoxazole resistance. Int J Infect Dis (2012), 16 (8): e 603-e607.
76. Turrientes MC, Baquero MR, Sanchez MB, Valdezate S, Escudero E, Berg G, et al. Polymorphic mutation frequencies of clinical and environmental Stenotrophomonas maltophilia populations. Appl Environ Microbiol (2010), 76 (6): 1746-1758.
77. Mukherjee P, Roy P. Cloning, sequencing and expression of novel tricholoroethylene degradation genes from Stenotrophomonas maltophilia PM102: a case of gene duplication. J Bioremed Biodeg (2013), 4:2, http:/dx.doi.org/10.4172/2155-6199.1000177.
78. Mukherjee P, Roy P. Copper enhanced monooxygenase activity and FT-IR spectroscopic characterization of biotransformation products in trichloroethylene degrading bacterium: Stenotrophomonas maltophilia PM102. BioMed Res Int (2013), http:/dx.doi.org/10.1155/2013.723680.
79. Mukherjee P, Roy P. Purification and identification of trichloroethylene induced proteins from Stenotrophomonas maltophilia PM102 by immuno-affinity-chromatography and MALDI-TOF mass spectrometry. Springer Plus (2013), 2: 207. http:/www.springerplus.com/content/2/1/207.
80. Hernandez A, Ruiz FM, Romero A, Martinez JL. The binding of triclosan to Sme T, the repressor of the multidrug efflux pump Sme DEF, induces antibiotic resistance in Stenotrophomonas maltophilia. PLoS Pathog (2011), 7 (6): e 1002103.doi: 10.1371/journal.pp at.1002103.
81. Kempf VA, Mandle T, Schumacher U, Schäfer A, Autenrieth IB. Rapid detection and identification of pathogens in blood cultures by fluorescence in site hydridization and flow cytometry. Int J Med Microbiol (2005) 295 (1): 47-55.
82. Gallo SW, Ramos PL, Sanchez Ferreira CA, de Oliveira SD. A specific polymerase chain reaction method to identify Stenotrophomonas maltophilia. Mem Inst Oswaldo Cruz (2013) 108 (3): 390-391.
83. Nakamura A, Sugimoto Y, Ohishi K, Sugawara Y, Fujieda A, Monma F, et al. Diagnostic value of PCR analysis of bacteria and fungi from blood in empiric-therapy-resistant febrile neutropenia. J Clin Microbiol (2010) 48 (6): 2030-2036.
84. Menezes LC, Rocchetti TT, de Castro Bauab K, Cappellano P, Quiles MG, Carlesse F, et al. Diagnosis by real-time polymerase chain reaction of pathogens and antimicrobial resistance genes in bone marrow transplant patients with bloodstream infections. BMC Infect Dis (2013), 13: 166.
85. Xu J, Moore JE, Miller BC, Alexander HD, McClurg R, Morris TC, et al. Improved laboratory diagnosis of bacterial and fungal infections in patients with hematological malignancies using PCR and ribosomal RNA sequence analysis. Leuk Lymphoma (2004), 45 (8): 1637-1641.
86. Lamoth F, Jaton K, Prod'hom G, Senn L, Bille J, Calandra T, et al. Multiplex blood PCR in combination with blood cultures for improvement of microbiological documentation of infection in febrile neutropenia. J Clin Microbiol 2010, 48 (10): 3510-3516.
87. von Lilienfeld-Toal M, Lehmann LE, Raadts AD, Hahn-Ast C, Orloop KS, Marklein G, et al. Utility of a commercially available multiplex real-time PCR assay to detect bacterial and fungal pathogens in febrile neutropenia. J Clin Microbiol (2009), 47 (8): 2405-2410.
88. Bravo D, Blanquer J, Tormo M, Aguillar G, Borras R, Solano C, et al. Diagnostic accuracy and potential clinical value of the LightCycler SeptiFast assay in the managment of bloodstream infections occurring in neutropenic and critically ill patients. Int J Infect Dis (2011), 15 (5): e 326-e 331.
89. Kassel TWK, Ryan LKL, Li A. Computed tomography features of Stenotrophomonas maltophilia pneumonia in patients with neutropenic fever: report of two cases. Multidiscip Respir Med (2013) 8 (14). http://www.mrmjournal.com/content/8/1/14.
90. Makis W, Ciarallo A, Rush C, Hickeson M. Infectious and inflammatory complications of surgical management of cancer patients imaged with 18 F-FDG PET/CT: a pictoral assay. Clin Imaging (2013) 37: 669-679.
91. Heussel CP, Kauczor H-U, Hessel G, Fischer B, Mildenberger P, Thelen M. Early detection of pneumonia in febrile neutropenic patients: use of thin-section CT. Am J Radiol (1997) 169: 1347-1353.
92. Heussel CP, Kauczor H-U, Heussel GE, Fisher B, Begrich M, Mildenberger P, et al. Pneumonia in febrile neutropenic patients and in bone marrow and blood stem cell transplant recipients: use of high resolution computed tomography. J Clin Oncol (1999) 17 (3): 796-805.
93. de Mattos Coelho, Gasparetto TD, Escuissato DL, Marchiori E. Bacterial pneumonia following bone marrow transplantation: HRCT findings. J Bras Pneumol (2009) 35 (5): 431-435.
94. Forslow U, Remberger M, Nordlander A, Mattsson J. The clinical importance of bronchoalveolar lavage in allogeneic SCT patients with pneumonia. Bone Marrow Transplant (2010) 45: 945-950.
95. Hofmeister CC, Czerlanis C, Forsythe S, StiffPJ. Retrospective utility of bronchoscopy after hematopoietic stem cell transplant. Bone Marrow Transplant (2006) 38: 693-698.
96. Shannon VR, Andersson BS, Lei X, Champlin RE, Kontoyiannis DP. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation. Bone Marrow Transplant (2010) 45: 647-655.
97. Maschmeyer G, Beinert T, Buchheidt D, Cornely OA, Einsele H, Heinz W, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: guidelines for the infectious diseases working party of the German Society of Hematology and Oncology. Eur J Cancer (2009) 45 (14): 2462-2472.
98. Wingard JR, Hiemenz JW, Jantz MA. How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation. Blood (2012) 120 (9): 1791-1800.
99. van Elden LJR, van Kraaij, Nijhuis M, Hendriksen KAW, Dekker Ad W, Rozenberg-Arska M. Polymerase chain reaction is more sensitive than viral culture and antigen testing for the detection of respiratory viruses in adults with hematological cancer and pneumonia. Clin Infect Dis (2002), 34: 177-183.
100. Murdoch DR. Nucleic acid amplification tests for the diagnosis of pneuomonia. Clin Infect Dis (2003), 36: 1162-1170.
101. Penzak SR, Abate BJ. Stenotrophomonas (xanthomonas) maltophilia: a multidrug-resistant nosocomial pathogen. Pharmacotherapy (1997) 17 (2): 293-301.
102. Al-Jasser AM. Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem. Ann Clin Microbiol Antimicrob (2006) 5: 23. doi: 10.1186/1476-0711-5-23.
103. Brown GR. Cotrimoxazole-optimal dosing in the critically ill. Ann Intens Care (2014) 4:13. doi: 10.1186/2110-5820-4-13
104. Church D, Lloyed T, Peirano G, Pitout J. Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates. Scand J Infect Dis (2013) 45 (4): 265-270.
105. Hornsey M, Longshaw C, Phee L, Wareham DW. In vitro activity of telavancin in combination with colistin versus Gram-negative bacterial pathogens. Antimicrob Agents Chemother (2012) 56 (6): 3080-3085.
106. Cho SY, Kang CI, Kim J, Ha YE, Chung DR, Lee NY et al. Can levofloxacin be a useful alternative to trimethoprimsulfamethoxazole for treating Stenotrophomonas maltophilia bacteremia? Antimicrob Agents Chemother (2014) 58 (1): 581-583.
107. Giamarellos-Bourboulis EJ, Kamesis L, Giamarellou H. Synergy of colistin with rifampicin and trimethoprimsulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis (2002), 44 (3): 259-263.
108. Avenbuch D, Horwitz E, Strahilevitz J, Stepenski P, Goldschmidt N, Gatt ME, et al. Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients. Infection (2013) 41(5): 991-997.
109. Passerini de Rossa B, Garcia C, Calenda M, Vay C, Franco M. Activity of levofloxacin and ciprofloxacin on biofilms and planktonic cells of Stenotrophomonas maltophilia isolates from patients with device-associated infections. Int J Antimicrob Agents (2009) 34 (3): 260-264.
110. Ioannides K, Myrianthefs P, Baltopoulos G. Colistin as a first choice antibiotic for the initial empiric antimicrobial therapy of ventilator-associated pneumonia. Eur Respir J (2007) 30 (6): 1234-1235.
111. Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-analysis. Clin Infect Dis (2012) 54 (5): 670-680.
112. Busca A, Cavecchia I, Locatelli F, D'Ardia S, De Rosa FG, Marmont F, et al. Bloodstream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis. Transpl Infect Dis (2012) 14 (1): 40-48.
113. Bonadio M, Morelli G, Mori S, Riccioni R, Papineschi F, Petrini F. Fluoroquinolone resistance in hematopoietic stem cell transplant recipients with infectious complications. Biomed Pharmacother (2005) 59 (9): 511-516.
114. Mahmoud A, Chevalier J, Alibert-Franco S, Kern WV, Pages J-M. Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J Antimicrob Chemother (2007) 59: 1223-1229. doi: 10.1093/jac/dk1493.
115. Zechini B, Versace I. Inhibitors of multidrug resistant efflux systems in bacteria. Recent Pat Antiinfect Drug Discov (2009) 4 (1): 37-50.
116. Pages JM, Sandrine AF, Mahmoud A, Bolla JM, Davin-Regli A, Chevalier J, et al. Efflux pumps of Gram-negative bacteria, a new target for new molecules. Curr Top Med Chem (2010) 10 (18): 1848-1857.
117. Leitner I, Nemeth J, Feurstein T, Abrahim A, Matzneller P, Lagler H, et al. The third-generation P-glycoprotein inhibitor tariquidar may overcome multidrug resistance by increasing intracellular drug concentration. J Antimicrob Chemother (2011) 66: 834-839.
118. Skurnik D, Davis Jr MR, Benedetti D, Moravec KL, Cywes-Bently C, Roux D, et al. Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. J Infect Dis (2012) 205: 1709-1718.
119. Devocelle M. Targeted antimicrobial peptides. Front Immun (2012) 3:309. doi: 10.3389/fimmu.2012.00309
120. Viertel TM, Ritter K, Horz H-P. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens. J Antimicrob Chemother (2014). Epub ahead of print: May 28, 2014. doi: 10.1093/jac/dku173
121. AboZahra R. Quorum sensing and interspecies interactions in Stenotrophomonas maltophilia. Br Microbiol Res J (2013) 3 (3): 414-422.
122. Bhardwaj AK, Vinothkumar K, Rajpara N. Bacterial quorum sensing inhibitors: attractive alternatives for control of infectious pathogens showing multiple drug resistance. Recent Pat Antiinfect Drug Discov (2013): 8 (1): 68-83.
123. Ronaldo PC. Small protein-mediated quorum sensing in a Gramnegative bacterium: novel targets for control of infectious disease. Discov Med (2011) 12 (67): 461-470.
124. Smalls FE. Development of an anti-Stenotrophomonas maltophilia immunoglobulin-G (IgG) that prevents iron transport in Gramnegative bacteria (2009). ETD Collection for Robert W. WoodruffLibrary, Atlanta University Center. Pager 76. http:/digitalcommons.auctr.edu/dissertation/76.
125. Garazi M, Singer C, Tai J, Ginocchio CC. Bloodstream infections caused by Stenotrophomonas maltophilia: a seven-year review. J Hosp Infect (2012) 81(2): 114-118.
126. Paez JI, Costa SF. Risk factors associated with mortality of infections caused by Stenotrophomonas maltophilia: a systematic review. J Hosp Infect (2008) 70 (2): 101-108.